Agios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 03, 2022 at 09:47 am EDT
Share
Agios Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 3.52 million. Net loss was USD 81.75 million compared to USD 88.77 million a year ago. Basic loss per share from continuing operations was USD 1.49 compared to USD 1.48 a year ago. Basic loss per share was USD 1.49 compared to USD 1.56 a year ago.
For the nine months, revenue was USD 9.93 million. Net loss was USD 268.33 million compared to net income of USD 1,699.34 million a year ago. Basic loss per share from continuing operations was USD 4.9 compared to USD 4.13 a year ago. Basic loss per share was USD 4.9 compared to basic earnings per share of USD 27.19 a year ago.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
AGIOS PHARMACEUTICALS, INC. 
